7 takeaways from FDA hearing on CBD and hemp

June 9, 2019 |

In Washington, D.C., last week, the Food and Drug Administration held a public hearing to determine a pathway toward regulating CBD. Mile High Labs Founder and CTO, Stephen Mueller spoke at this hearing and provided 7 recommendations to the FDA. He said “Don’t wait to regulate. CBD is rapidly becoming a preferred ingredient in everything from lip balm to pet food. According to a recent study by Consumer Reports, 64 million Americans have tried CBD in the past 24 months. With so many stories touting the benefits of CBD, demand is rising and so too will the supply, with some experts estimating it will “soon become a $22 billion industry. Simply put, the market is growing too fast and the public demand is too high for the FDA to wait to act.

His recommendations include starting with labeling requirements, enforcing testing standards, requiring good manufacturing practices, regulating dietary supplements, foods and cosmetics at lower strengths, requiring new dietary ingredient notifications, evaluate each cannabinoid separately, require testing for contaminants.

Print Friendly, PDF & Email

Tags: , ,

Category: Policy

Thank you for visting the Digest.